Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 10/20 | 0.44 |
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986391 | 0.91 | IDO1 (0.48) | CNR2CNR1TPSAB1IDO1 | |
| SCHEMBL12643105 | 0.91 | CNR2 (0.44) | CNR2CNR1TPSAB1IDO1MAPT | |
| SCHEMBL12642925 | 0.88 | CNR2 (0.47) | ALDH1A1CNR2CNR1TPSAB1RORC | |
| SCHEMBL2036957 | 0.87 | RORC (0.43) | ALDH1A1CNR2RORCIDO1MAPT | |
| SCHEMBL2037470 | 0.86 | ALDH1A1 (0.42) | ALDH1A1CNR2RORCIDO1MAPT | |
| SCHEMBL2038066 | 0.86 | CNR2 (0.56) | ALDH1A1CNR2CNR1TPSAB1RORC | |
| SCHEMBL2040698 | 0.85 | CNR2 (0.52) | ALDH1A1CNR2CNR1RORC | |
| SCHEMBL2038751 | 0.84 | ALDH1A1 (0.46) | ALDH1A1CNR2CNR1MAPTMEN1 | |
| SCHEMBL2036074 | 0.83 | P2RX7 (0.47) | ALDH1A1CNR2CNR1TPSAB1MAPT | |
| SCHEMBL1983582 | 0.82 | CNR2 (0.49) | ALDH1A1CNR2CNR1TPSAB1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| EP-2516428-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120238600-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| WO-2011087652-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011079103-A1 | SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079103-A1 | SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238600-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | ALDH1A1 202/4885CNR2 326/4885CNR1 261/4885 |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | ALDH1A1 752/4885CNR2 113/4885CNR1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.